Oregon Public Employees Retirement Fund Maintains Position in Illumina, Inc. (ILMN)
Oregon Public Employees Retirement Fund maintained its stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,299 shares of the life sciences company’s stock at the end of the second quarter. Oregon Public Employees Retirement Fund’s holdings in Illumina were worth $2,655,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Advocacy Wealth Management Services LLC bought a new position in Illumina during the first quarter valued at $102,000. Advisory Services Network LLC bought a new position in Illumina during the first quarter valued at $117,000. Gemmer Asset Management LLC raised its position in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares in the last quarter. Patten Group Inc. raised its position in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. raised its position in Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares in the last quarter. 93.75% of the stock is owned by institutional investors and hedge funds.
Shares of Illumina, Inc. (NASDAQ:ILMN) opened at 173.85 on Wednesday. The firm has a 50-day moving average of $175.17 and a 200-day moving average of $171.09. The company has a market capitalization of $25.38 billion, a P/E ratio of 35.19 and a beta of 0.84. Illumina, Inc. has a one year low of $119.37 and a one year high of $189.48.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm had revenue of $598 million for the quarter, compared to the consensus estimate of $590.51 million. During the same period in the previous year, the company earned $0.71 earnings per share. The company’s quarterly revenue was up 4.5% on a year-over-year basis. Equities research analysts expect that Illumina, Inc. will post $3.63 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/07/26/oregon-public-employees-retirement-fund-maintains-position-in-illumina-inc-ilmn.html.
Several research firms have weighed in on ILMN. BidaskClub lowered shares of Illumina from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Canaccord Genuity restated a “hold” rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $190.90 price target on the stock in a research note on Tuesday, April 4th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price target on the stock in a research note on Tuesday, April 4th. Finally, Leerink Swann restated a “buy” rating on shares of Illumina in a research note on Wednesday, April 5th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $167.49.
In other Illumina news, insider Michel Bouchard sold 5,740 shares of the company’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $184.68, for a total value of $1,060,063.20. Following the transaction, the insider now directly owns 22,255 shares in the company, valued at $4,110,053.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total transaction of $300,995.63. Following the completion of the transaction, the senior vice president now owns 10,936 shares in the company, valued at $2,045,797.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 125,248 shares of company stock worth $22,281,673. Corporate insiders own 1.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.